It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with other antipsychotics (very low certainty).
Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
Perazine showed no clear difference in acceptability of treatment Leaving the studies early due to any reason compared with other antipsychotics (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Perazine may leads to lower global state change over time (no better or deterioration) compared with placebo (low certainty).
Perazine showed no clear difference in overall mental state less than 30% BPRS reduction compared with placebo (low certainty).
It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with placebo (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Perazine showed no clear difference in global state change over time (no better or deterioration) compared with other antipsychotics (low certainty).
Trifluoperazine showed no clear difference in response to treatment ‐ medium term compared with low‐potency antipsychotic drugs (low certainty).
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
Trifluoperazine showed no clear difference in adverse events: 1. General ‐ at least one adverse effect compared with low‐potency antipsychotic drugs (moderate certainty).
Trifluoperazine showed no clear difference in adverse events: 2.a. Specific ‐ movement disorders ‐ at least one… compared with low‐potency antipsychotic drugs (low certainty).